VIM
AUPH icon

Vinva Investment Management’s Aurinia Pharmaceuticals AUPH Stock Holding History

Vinva Investment Management’s Portfolio AUPH Stock Details AUPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$389K Hold
15,958
– – ﹤0.01% 431
2026
Q1 		$325K Buy
+15,958
New +$233K ﹤0.01% 416

Other funds holding AUPH

TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vinva Investment Management's AUPH Position: Q2 2026 in Review

Vinva Investment Management held its Aurinia Pharmaceuticals (AUPH) position steady in Q2 2026 at 15,958 shares worth $389K. The position accounts for ﹤0.01% of the portfolio, ranked #431.

Vinva Investment Management first reported a position in AUPH in Q1 2026 and has held it in 2 quarters since. 282 funds tracked by Wall St. Rank hold AUPH as of Q2 2026.

  • Vinva Investment Management held 15,958 shares of Aurinia Pharmaceuticals worth $389K as of Q2 2026.
  • Vinva Investment Management left its Aurinia Pharmaceuticals share count unchanged in Q2 2026.
  • Aurinia Pharmaceuticals made up ﹤0.01% of Vinva Investment Management's portfolio in Q2 2026, its #431 holding.
  • Vinva Investment Management first reported a position in Aurinia Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • 282 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q2 2026.

Based on Vinva Investment Management's 13F filing for Q2 2026, filed 14 Aug 2026.